文献速递产科母胎医学

妊娠期子痫前期与COVID-19的内皮及血管生成特征差异与相似性

Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy.
PubMed 文献 · Am J Obstet Gynecol · 2022-03-26

本研究比较妊娠期子痫前期与COVID-19患者血浆内皮损伤、凝血、先天免疫及血管生成标志物,并体外观察患者血清对内皮细胞的影响。结果显示轻型COVID-19标志物谱与对照相似,子痫前期与重型COVID-19虽均有内皮功能障碍,但循环标志物谱不同,可用于鉴别诊断。

要点

  • 轻型COVID-19孕妇的循环生物标志物谱与正常妊娠对照相似。
  • 子痫前期与重型COVID-19呈现不同的循环生物标志物谱,可助鉴别。
  • 子痫前期患者血清诱导内皮细胞ICAM-1和vWF过表达,但弱于重型COVID-19。

核心结论

  • 子痫前期与重型COVID-19在体外均引起内皮功能障碍,但循环生物标志物谱不同,涉及内皮损伤、凝血病及血管生成失衡,可能有助于两者鉴别诊断。

研究设计与样本

  • 获取孕妇血浆和血清:轻型COVID-19(n=10)、重型COVID-19(n=9)、血压正常妊娠对照(n=10)及子痫前期患者(n=13)。
  • 检测血管细胞黏附分子-1、可溶性肿瘤坏死因子受体I、硫酸乙酰肝素、血管性血友病因子抗原(活性及多聚体模式)、α2-抗纤溶酶、C5b9、中性粒细胞胞外诱捕网、胎盘生长因子、可溶性fms样酪氨酸激酶-1及血管生成素2等血浆生物标志物。
  • 将微血管内皮细胞暴露于患者血清,用免疫荧光评估细胞膜细胞间黏附分子1表达及细胞外基质血管性血友病因子释放,并检测p38丝裂原活化蛋白激酶磷酸化。
  • 统计分析包括单变量和多变量方法。

主要发现

  • 轻型COVID-19患者生物标志物谱与对照相似。
  • 重型COVID-19较对照有更高浓度的血管细胞黏附分子-1、可溶性肿瘤坏死因子-α受体I、硫酸乙酰肝素、血管性血友病因子抗原及中性粒细胞胞外诱捕网,胎盘生长因子显著降低。
  • 子痫前期较对照及重型COVID-19患者血管细胞黏附分子-1和可溶性肿瘤坏死因子-α受体I显著升高,血管性血友病因子抗原、血管性血友病因子活性及α2-抗纤溶酶显著降低。
  • 子痫前期还观察到胎盘生长因子降低、可溶性fms样酪氨酸激酶-1和血管生成素2升高,可溶性fms样酪氨酸激酶-1与胎盘生长因子比值非常高;较对照C5b9和中性粒细胞胞外诱捕网显著增加。
  • 主成分分析显示子痫前期与其他组明显分离(第一和第二主成分分别解释42.2%和13.5%的方差),主要区分变量为血管性血友病因子、可溶性肿瘤坏死因子受体I、硫酸乙酰肝素和可溶性fms样酪氨酸激酶-1。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: COVID-19 presents a spectrum of signs and symptoms in pregnant women that might resemble preeclampsia. Differentiation between severe COVID-19 and preeclampsia is difficult in some cases. OBJECTIVE: To study biomarkers of endothelial damage, coagulation, innate immune response, and angiogenesis in preeclampsia and COVID-19 in pregnancy in addition to in vitro alterations in endothelial cells exposed to sera from pregnant women with preeclampsia and COVID-19. STUDY DESIGN: Plasma and sera samples were obtained from pregnant women with COVID-19 infection classified into mild (n=10) or severe (n=9) and from women with normotensive pregnancies as controls (n=10) and patients with preeclampsia (n=13). A panel of plasmatic biomarkers was assessed, including vascular cell adhesion molecule-1, soluble tumor necrosis factor-receptor I, heparan sulfate, von Willebrand factor antigen (activity and multimeric pattern), α2-antiplasmin, C5b9, neutrophil extracellular traps, placental growth factor, soluble fms-like tyrosine kinase-1, and angiopoietin 2. In addition, microvascular endothelial cells were exposed to patients' sera, and changes in the cell expression of intercellular adhesion molecule 1 on cell membranes and von Willebrand factor release to the extracellular matrix were evaluated through immunofluorescence. Changes in inflammation cell signaling pathways were also assessed by of p38 mitogen-activated protein kinase phosphorylation. Statistical analysis included univariate and multivariate methods. RESULTS: Biomarker profiles of patients with mild COVID-19 were similar to those of controls. Both preeclampsia and severe COVID-19 showed significant alterations in most circulating biomarkers with distinctive profiles. Whereas severe COVID-19 exhibited higher concentrations of vascular cell adhesion molecule-1, soluble tumor necrosis factor-α receptor I, heparan sulfate, von Willebrand factor antigen, and neutrophil extracellular traps, with a significant reduction of placental growth factor compared with controls, preeclampsia presented a marked increase in vascular cell adhesion molecule-1 and soluble tumor necrosis factor-α receptor I (significantly increased compared with controls and patients with severe COVID-19), with a striking reduction in von Willebrand factor antigen, von Willebrand factor activity, and α2-antiplasmin. As expected, reduced placental growth factor, increased soluble fms-like tyrosine kinase-1 and angiopoietin 2, and a very high soluble fms-like tyrosine kinase-1 to placental growth factor ratio were also observed in preeclampsia. In addition, a significant increase in C5b9 and neutrophil extracellular traps was also detected in preeclampsia compared with controls. Principal component analysis demonstrated a clear separation between patients with preeclampsia and the other groups (first and second components explained 42.2% and 13.5% of the variance), mainly differentiated by variables related to von Willebrand factor, soluble tumor necrosis factor-receptor I, heparan sulfate, and soluble fms-like tyrosine kinase-1. Von Willebrand factor multimeric analysis revealed the absence of von Willebrand factor high-molecular-weight multimers in preeclampsia (similar profile to von Willebrand disease type 2A), whereas in healthy pregnancies and COVID-19 patients, von Willebrand factor multimeric pattern was normal. Sera from both preeclampsia and severe COVID-19 patients induced an overexpression of intercellular adhesion molecule 1 and von Willebrand factor in endothelial cells in culture compared with controls. However, the effect of preeclampsia was less pronounced than the that of severe COVID-19. Immunoblots of lysates from endothelial cells exposed to mild and severe COVID-19 and preeclampsia sera showed an increase in p38 mitogen-activated protein kinase phosphorylation. Patients with severe COVID-19 and preeclampsia were statistically different from controls, suggesting that both severe COVID-19 and preeclampsia sera can activate inflammatory signaling pathways. CONCLUSION: Although similar in in vitro endothelial dysfunction, preeclampsia and severe COVID-19 exhibit distinctive profiles of circulating biomarkers related to endothelial damage, coagulopathy, and angiogenic imbalance that could aid in the differential diagnosis of these entities.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Palomo M, Youssef L, Ramos A, et al. Differences and similarities in endothelial and angiogenic profiles of preeclampsia and COVID-19 in pregnancy. Am J Obstet Gynecol. 2022. PMID: 35351411. doi:10.1016/j.ajog.2022.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。